Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Files BLA For Conjugated Herceptin Follow-On Trastuzumab-DM1

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche's next-generation conjugated Herceptin could be on the market for HER2-positive breast cancer patients as soon as the first quarter of 2011, if the application gets a priority review. Roche's wholly owned subsidiary Genentech announced it had filed the trastuzumab-DM1 biologic license application July 7, asking for accelerated approval and a six-month review turnaround
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS004504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel